NEW YORK, June 11, 2013 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Dynavax Technologies Corporation ("Dynavax" or the "Company") (NasdaqCM: DVAX -News). The investigation focuses on whether the Company and its executives violated federal securities laws.
On June 10, 2013, shares of Dynavax fell as much as 42% after reporting its findings from a meeting with the Food and Drug Administration ("FDA") over its biologic license application for hepatitis-B vaccine Heplisav. Dynavax said the FDA wants it to get safety data from more patients. The agency added that analyzing the drug for smaller groups of patients did not fully address its concerns. In addition to understanding what the FDA would like to see in additional safety trials, Dynavax also has manufacturing concerns to contend with as noted by the FDA in its complete response letter to the company. The investigation focuses on whether a series of statements by the Company regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
If you are aware of any facts relating to this investigation, or purchased shares of Dynavax, you can assist this investigation by contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts